marknteladvisors.

com

GCC Oncology/Cancer
Drugs Market Analysis,
2020
Document Outline

Introduction
02
About Us, Key Questions Answered In This Study

Table of Content 05
Market Segmentation, Scope of Work

Research Process & Methodology

Primary Research, Secondary Research, Companies Interviewed, Respondent Profile, Research 13
Methodology, Forecasting

Sample Pages 21
GCC Oncology/Cancer Drugs Market Analysis, 2020

Commercials 43

Disclaimer 45

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 2

Market Segmentation

GCC Oncology/Cancer Drugs Market Segmentation

By Therapy By Region By Application By Company

• Chemotherapy • Breast Cancer • Hoffmann-La Roche Ltd.

• UAE

• Immunotherapy • Lung Cancer • Johnson & Johnson Middle

• Saudi Arabia

• Targeted Therapy • Kidney Cancer East FZ LLC

• Oman

• Radiation • Liver cancer • Pfizer International

• Bahrain

• Surgical • Ovarian Cancer Corporation

• Kuwait

• Others • Prostate Cancer • Merck Serono Middle East FZ-

• Qatar

• Skin Cancer Ltd.

• Pancreatic Cancer • AbbVie Biopharmaceuticals

• Colorectal Cancer GmbH

• Blood Cancer • AstraZeneca Gulf FZ LLC

• Others • Bayer Middle East FZE

• Amgen Inc.

• Astellas MENA/SSA

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 3

 Historical Year: 2015
Base Year: 2019
Table of Content (1/6) Forecast Year: 2025
Table of Content
1. Introduction
1.1. Product Definition
1.2. Research Process
1.3. Market Segmentation
1.4. Assumptions
2. Executive Summary
3. GCC Market Overview
4. Impact of COVID-19 on GCC Oncology/Cancer Drugs Market
5. Expert Verbatim-Interview Excerpts of industry experts
6. GCC Oncology/Cancer Drugs Market Outlook, 2015-2025
6.1. Market Size & Analysis
6.1.1. Revenues
6.2. Market Share & Analysis
6.2.1. By Therapy
6.2.1.1. Chemotherapy
6.2.1.2. Immunotherapy
6.2.1.3. Targeted Therapy
6.2.1.4. Radiation
6.2.1.5. Surgical
6.2.1.6. Others

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 4

 Historical Year: 2015
Base Year: 2019
Table of Content (2/6) Forecast Year: 2025
Table of Content
6.2.2. By Application
6.2.2.1. Breast Cancer
6.2.2.2. Lung Cancer
6.2.2.3. Kidney Cancer
6.2.2.4. Liver cancer
6.2.2.5. Ovarian Cancer
6.2.2.6. Prostate Cancer
6.2.2.7. Skin Cancer
6.2.2.8. Pancreatic Cancer
6.2.2.9. Colorectal Cancer
6.2.2.10. Blood Cancer
6.2.2.11. Others
6.2.3. By Region
6.2.3.1. UAE
6.2.3.2. Saudi Arabia
6.2.3.3. Oman
6.2.3.4. Bahrain
6.2.3.5. Kuwait
6.2.3.6. Qatar
6.2.4. By Company

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 5

 Historical Year: 2015
Base Year: 2019
Table of Content (3/6) Forecast Year: 2025
Table of Content
6.2.4.1. Market Shares, By Revenue
6.2.4.2. Strategic Factorial Indexing
6.2.4.3. Competitor Placement in MarkNtel Quadrant
6.3. Market Attractiveness Index
6.3.1. By Therapy
6.3.2. By Application
6.3.3. By Region
7. UAE Oncology/Cancer Drugs Market Outlook, 2015-2025
7.1. Market Size & Analysis
7.1.1. Revenues
7.2. Market Share & Analysis
7.2.1. By Therapy
7.2.2. By Application
8. Saudi Arabia Oncology/Cancer Drugs Market Outlook, 2015-2025
8.1. Market Size & Analysis
8.1.1. Revenues
8.2. Market Share & Analysis
8.2.1. By Therapy
8.2.2. By Application
9. Oman Oncology/Cancer Drugs Market Outlook, 2015-2025

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 6

 Historical Year: 2015
Base Year: 2019
Table of Content (4/6) Forecast Year: 2025
Table of Content
9.1. Market Size & Analysis
9.1.1. Revenues
9.2. Market Share & Analysis
9.2.1. By Therapy
9.2.2. By Application
10. Bahrain Oncology/Cancer Drugs Market Outlook, 2015-2025
10.1. Market Size & Analysis
10.1.1. Revenues
10.2. Market Share & Analysis
10.2.1. By Therapy
10.2.2. By Application
11. Kuwait Oncology/Cancer Drugs Market Outlook, 2015-2025
11.1. Market Size & Analysis
11.1.1. Revenues
11.2. Market Share & Analysis
11.2.1. By Therapy
11.2.2. By Application
12. Qatar Oncology/Cancer Drugs Market Outlook, 2015-2025
12.1. Market Size & Analysis
12.1.1. Revenues

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 7

 Historical Year: 2015
Base Year: 2019
Table of Content (5/6) Forecast Year: 2025
Table of Content
12.2. Market Share & Analysis
12.2.1. By Therapy
12.2.2. By Application
13. GCC Oncology/Cancer Drugs Market Policies, Regulations, Product Standards
14. GCC Oncology/Cancer Drugs Market Trends & Insights
15. GCC Oncology/Cancer Drugs Market Dynamics
15.1. Growth Drivers
15.2. Challenges
15.3. Impact Analysis
16. GCC Oncology/Cancer Drugs Market Hotspot & Opportunities
17. GCC Oncology/Cancer Drugs Market Key Strategic Imperatives for Success & Growth
18. Competition Outlook
18.1. Competition Matrix
18.1.1. Product Portfolio
18.1.2. Target Markets
18.1.3. Research & Development
18.1.4. Strategic Alliances
18.1.5. Strategic Initiatives
18.2. Company Profiles of Top Companies (Business Description, Product Segments, Business Segments, Financials,
Strategic Alliances/ Partnerships, Future Plans)
18.2.1. Hoffmann-La Roche Ltd.

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 8

 Historical Year: 2015
Base Year: 2019
Table of Content (6/6) Forecast Year: 2025
Table of Content
18.2.2. Johnson & Johnson Middle East FZ LLC
18.2.3. Pfizer International Corporation
18.2.4. Merck Serono Middle East FZ-Ltd.
18.2.5. AbbVie Biopharmaceuticals GmbH
18.2.6. AstraZeneca Gulf FZ LLC
18.2.7. Bayer Middle East FZE
18.2.8. Amgen, Inc.
18.2.9. Astellas MENA/SSA
19. Disclaimer

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 9

Document Outline

Introduction
02
About Us, Key Questions Answered In This Study

Table of Content 05
Market Segmentation, Scope Of Work

Research Process & Methodology

Primary Research, Secondary Research, Companies Interviewed, Respondent Profile, Research 13
Methodology, Forecasting

Sample Pages 21
GCC Oncology/Cancer Drugs Market Analysis, 2020

Commercials 43

Disclaimer 45

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 10

 GCC Oncology/Cancer Drugs Market Outlook, 2015-2025F

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved.

GCC Oncology/Cancer Drugs Market Outlook, By Revenues
Figure XX: GCC Oncology/Cancer Drugs Market Revenues (USD Million), 2015 - 2025F

Revenue: XX% Revenue: XX%

CAGR
CAGR

2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F

Source: MarkNtel Advisors

• The GCC oncology/cancer drugs market is augmenting over the past couple of years. The availability of generic drugs, reimbursement
policy, and rising tobacco smoking are the main factors that contributed to the growth of the market. Tobacco smoking is a key reason for
diagnosed lung, urinary bladder, and colorectal cancer among male individuals in GCC. With the surging number of such cancer patients in
the region, the demand for cancer drugs is flourishing through 2015.
• The outbreak of COVID-19 has generated a situation of lockdown and overburden of patients in healthcare settings. Due to this reason, the
low-risk cancer procedures and diagnostic tests of cancer were suspended, which leads to lesser number of new cancer patients
diagnosed in early 2020 in the gulf countries. However, with the marginalizing impact of COVID-19, the demand for cancer drugs is set to
proliferate during the forecast period.

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 12

GCC Oncology/Cancer Drugs Market Size, By Therapy
Figure XX: GCC Oncology/Cancer Drugs Market Size (USD Million), By Therapy, 2019 & 2025F

2019 2025F

Chemotherapy Chemotherapy

Surgical Surgical

Radiation Radiation

Targeted Therapy Targeted Therapy

Immunotherapy Immunotherapy

Others Others

*These are dummy charts and do not represent actual value Source: MarkNtel Advisors

• Targeted Therapy: The growing adoption of advanced therapies for the treatment of cancer amid end-users in the region has been
generating the demand for targeted drugs over the last few years. Furthermore, the increasing demand for combination therapy for cancer
treatment also driving the additional sales of targeted drugs since 2015. For instance: use of targeted therapy with chemotherapy, targeted
therapy with immunotherapy, etc. These are among few of the key factors that contributed to the positive growth of the targeted therapy
segment in the Gulf region.
• Breast, lung, and colorectal cancer are majorly diagnosed in the population of GCC, and targeted therapy is widely used for the treatment
of such cancers over the past couple of years. The mushrooming cases of such cancers in the region vaticinated to propel the utilization of
targeted therapy. Thus, the market revenue of the targeted therapy segment would flourish by 2025.

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 13

GCC Oncology/Cancer Drugs Market Revenue Share, By Application
Figure XX: GCC Oncology/Cancer Drugs Market Revenue Share (%), By Application, 2019 & 2025F

Breast Cancer
Lung Cancer
Kidney Cancer
Liver cancer
Ovarian Cancer
2019 Prostate Cancer
2025F
Skin Cancer
Pancreatic Cancer
Colorectal Cancer
Blood Cancer
Others

*These are dummy charts and do not represent actual value Source: MarkNtel Advisors

• Breast Cancer: This is among the prime segment that supports the GCC oncology/cancer drugs market to grow over the past few years.
Breast cancer is the most common cancer diagnosed among women aged less than 50 years in the region due to overweight. The
increasing prevalence of overweight has been surging the risk of developing breast cancer among women, thus anticipated that the
demand for oncology drugs would increase during 2020-25.
• The growing awareness about early diagnosis among individuals expected to surge the number of breast cancer patients in the gulf
countries. Moreover, the increasing pharmaceutical companies' focus to launch new drugs for effective treatment of breast cancer has
been soaring the drug pipeline. Hence, the market share of the segment would escalate by 2025.

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 14

GCC Oncology/Cancer Drugs Market Revenue Share, By Region
Figure XX: GCC Oncology/Cancer Drugs Market Revenue Share (%), By Region, 2019 & 2025F

CAGR
Country 2019 2025F
(2020-25)

Kuwait UAE XX% XX% XX%

Bahrain Saudi Arabia XX% XX% XX%

Qatar
Saudi Arabia
UAE Oman XX% XX% XX%

Oman
Qatar XX% XX% XX%

Kuwait XX% XX% XX%

Bahrain XX% XX% XX%

Source: MarkNtel Advisors

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 15

UAE Oncology/Cancer Drugs Market Outlook, By Revenues
Figure XX: UAE Oncology/Cancer Drugs Market Revenues (USD Million), 2015 - 2025F

Revenue: XX% Revenue: XX%

CAGR
CAGR

2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F

Source: MarkNtel Advisors

• The UAE oncology/cancer drugs market dominated the GCC market over the past few years. The UAE market has foreseen a positive
growth due to initiatives taken by the government and organizations. The country’s healthcare expenditure is set to grow at a aCAGR of
around 5% during 2020-25. In addition, the government sponsored cancer research programs in collaboration with foreign research
centers is set to have a positive impact on cancer drugs market. The Emirates Oncology Society (EOS) collaborated with AstraZeneca in
2020 for generating awareness among individuals and mass screening of cancer to decline the mortality rate of cancer by 18% by 2021.
The patients diagnosed with cancer is anticipated to escalate and would add more demand for oncology cancer in the coming years.
• In addition, several non profit organization are also playing an anchor role in creating awareness about cancer among individuals in UAE.
For instance: Friends of Cancer Patients (FOCP), a non-profit organization has launched Ramadan Zakat Campaign “I Deserve a Life” in

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 16

 +1 (613) 707-5086

sales@marknteladvisors.com

Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 17